Marketdash
Back to News

Regeneron's Eylea HD Gets FDA Approval for Vision Loss Treatment With Fewer Injections

MarketDash Editorial Team
17 days ago
The FDA just approved Regeneron's Eylea HD for treating retinal vein occlusion, potentially cutting patient injections in half while adding flexible dosing options across multiple eye diseases.

Regeneron Pharmaceuticals Inc. (REGN) scored FDA approval on Wednesday for Eylea HD (aflibercept) Injection 8 mg in patients with macular edema following retinal vein occlusion. Here's why it matters: patients can now receive treatment every 8 weeks after an initial monthly dosing period, potentially halving the number of injections compared to existing therapies.

Retinal vein occlusion happens when one of the veins draining blood from the retina gets blocked, causing blood and fluid to leak out and potentially damaging vision. It's not a minor inconvenience—left untreated, it can lead to serious vision loss.

The FDA also greenlit a monthly dosing option for patients who might need more frequent treatment across all approved Eylea HD indications: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. That's four different eye diseases where doctors now have more tools in their kit.

"Eylea HD is the first treatment for retinal vein occlusion that can potentially cut the number of injections that patients receive in half compared to existing therapies. And with the addition of a monthly dosing option for all four approved Eylea HD indications, physicians now have greater flexibility and optionality to tailor treatment to meet individual patient needs," said George Yancopoulos, Regeneron's co-founder, board co-chair, president and chief scientific officer.

The approval rests on data from the Phase 3 QUASAR trial, which pitted Eylea HD against the standard Eylea (aflibercept) Injection 2 mg in patients with retinal vein occlusion. QUASAR hit its primary endpoint at 36 weeks, demonstrating that patients receiving Eylea HD every 8 weeks (after either 3 or 5 monthly doses) achieved non-inferior visual acuity gains compared to those getting standard Eylea every 4 weeks. The results held up consistently across patients with branch retinal vein occlusions and those with central retinal or hemiretinal vein occlusions.

On the manufacturing front, Regeneron continues working with Catalent Indiana, LLC (part of Novo Nordisk A/S) to resolve issues flagged during a July 2025 FDA site inspection that weren't specific to Eylea HD. The company also plans to submit an application to the FDA for an alternate pre-filled syringe manufacturing filler for Eylea HD by January 2026.

Price Action: REGN stock jumped 6.26% to $746.72 on Thursday.

Back to News

Regeneron's Eylea HD Gets FDA Approval for Vision Loss Treatment With Fewer Injections

MarketDash Editorial Team
17 days ago
The FDA just approved Regeneron's Eylea HD for treating retinal vein occlusion, potentially cutting patient injections in half while adding flexible dosing options across multiple eye diseases.

Regeneron Pharmaceuticals Inc. (REGN) scored FDA approval on Wednesday for Eylea HD (aflibercept) Injection 8 mg in patients with macular edema following retinal vein occlusion. Here's why it matters: patients can now receive treatment every 8 weeks after an initial monthly dosing period, potentially halving the number of injections compared to existing therapies.

Retinal vein occlusion happens when one of the veins draining blood from the retina gets blocked, causing blood and fluid to leak out and potentially damaging vision. It's not a minor inconvenience—left untreated, it can lead to serious vision loss.

The FDA also greenlit a monthly dosing option for patients who might need more frequent treatment across all approved Eylea HD indications: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. That's four different eye diseases where doctors now have more tools in their kit.

"Eylea HD is the first treatment for retinal vein occlusion that can potentially cut the number of injections that patients receive in half compared to existing therapies. And with the addition of a monthly dosing option for all four approved Eylea HD indications, physicians now have greater flexibility and optionality to tailor treatment to meet individual patient needs," said George Yancopoulos, Regeneron's co-founder, board co-chair, president and chief scientific officer.

The approval rests on data from the Phase 3 QUASAR trial, which pitted Eylea HD against the standard Eylea (aflibercept) Injection 2 mg in patients with retinal vein occlusion. QUASAR hit its primary endpoint at 36 weeks, demonstrating that patients receiving Eylea HD every 8 weeks (after either 3 or 5 monthly doses) achieved non-inferior visual acuity gains compared to those getting standard Eylea every 4 weeks. The results held up consistently across patients with branch retinal vein occlusions and those with central retinal or hemiretinal vein occlusions.

On the manufacturing front, Regeneron continues working with Catalent Indiana, LLC (part of Novo Nordisk A/S) to resolve issues flagged during a July 2025 FDA site inspection that weren't specific to Eylea HD. The company also plans to submit an application to the FDA for an alternate pre-filled syringe manufacturing filler for Eylea HD by January 2026.

Price Action: REGN stock jumped 6.26% to $746.72 on Thursday.

    Regeneron's Eylea HD Gets FDA Approval for Vision Loss Treatment With Fewer Injections - MarketDash News